openPR Logo
Press release

Global Companion Diagnostics – Growth Companion for Personalized Medicine

03-09-2017 02:44 PM CET | Health & Medicine

Press release from: Global Companion Diagnostics Therapy

Global Companion Diagnostics – Growth Companion

Companion Diagnostics: Growth Companion for Personalized Medicine

Personalized medicine is the new segment in discussion among healthcare experts around the globe. Also, encouragement from the regulatory bodies such as the FDA and EMEA in erms of providing a defined structure for companion diagnostic development is driving research activities in personalized medicine. Diagnosis at molecular level for each individual is of prime importance to identify the target biomarker before deciding the therapy. Companion diagnostic is one such emerging field for target biomarker identification reducing clinical trial cost and time to market the product.

For More Information Request FREE Sample PDF Brochure: https://www.coherentmarketinsights.com/insight/request-sample/109

Pharmaceutical companies need to constantly innovate and integrate latest technological breakthroughs in order to sustain in the market, given the looming threat of new technologies posing threat to existing product portfolio and research pipeline. Novartis AG focuses on R&D for biomarkers with the help of its partner SomaLogic, Inc., once they begin the process of finalizing the drug candidate. Such pre-work is now part of the routine of drug development, something that was an alien practice till around a decade ago. The U.S. FDA released a draft guideline for companion diagnostics in July 2016, providing a structure for the pharmaceutical companies to co-develop CDx test along with the drug therapies.

The global companion diagnostics market was valued at US$ 1,614.5 million in 2015 and is expected to witness a robust CAGR of 12.0% during the forecast period (2016 – 2024).

Potential lowering of cost and clinical benefits driving the companion diagnostics market

Growth of companion diagnostics relies on the ecosystem of pharmaceuticals industry. A more collaborative approach would benefit payors and providers of healthcare products and services. CDx supports drug developers in reducing development costs, develop highly effective therapeutic product, and improve the time to market by identifying the effectiveness of a drug against particular biomarkers. The payors (patients) benefit from better treatment outcomes and lower morbidity risk. Moreover, with the advent of advanced technologies such as PCR, immunohistochemistry and gene sequencing, accurate diagnosis, and determination of targeted cancer therapy is much easier.

Advancements in technology and increasing research on CDx has resulted in increasing approval of drug therapies with diagnostic tests alongside it. As per the Regulatory Affirms Professionals Society (RAPS), the share of drugs and biologics approved alongside a diagnostic test, by the U.S. FDA, increased from 20% in 2014 to 28% in 2015.

Ask for FREE Request Customization @ https://www.coherentmarketinsights.com/insight/request-customization/109

Research collaborations to improve the time to market

An integrated and more evidence-based approach is driving partnerships in the field of companion diagnostics. According to Wildwood Ventures Ltd., the number of global deal in CDx market has increased from 13 in 2007 to 66 in 2013. Since, developing CDx test along with drug therapy is a capital intensive and complex process, industry players are collaborating to leverage on each other’s expertise. For instance:

• Invivoscribe Technologies Inc., collaborated with Novartis AG and Astellas Pharma Inc. to develop companion diagnostics for their drugs under pipeline.

• Invivoscribe also announced a long-term partnership with Thermo Fisher Scientific in January 2017, develop and commercialize IVD assays for Applied Biosystems® 3500 Dx Series Genetic Analyzers. Invivoscribe Technologies Inc. is a global company engaged in providing clonality and biomarker test solutions for oncology and personalized molecular diagnostics.

• AstraZeneca plc entered into a deal with Abbott Laboratories, Inc. in 2015, to develop a companion diagnostic test for tralokinumab, used for treating severe asthma.

• Singulex, Inc. entered into a strategic collaboration with QIAGEN N.V. in January 2017 to develop companion diagnostics using Singulex's proprietary Single Molecule Counting (SMC) immunodiagnostic platform
Increasing number of research collaborations is expected to improve the time to market of highly effective targeted drug therapies.

Browse Press Release : https://www.coherentmarketinsights.com/press-release/companion-diagnostics-market-to-surpass-us-50-billion-by-2024-20

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Companion Diagnostics – Growth Companion for Personalized Medicine here

News-ID: 463350 • Views: 351

More Releases for CDx

Companion Diagnostic (CDx) Market Outlook & Growth Prediction 2022 By Leading Pl …
Stratagem Market Insights recently published a research report titled, "Companion Diagnostic (CDx) Market - Increase in Demand and Opportunities 2022". The research report attempts to give a holistic overview of the Companion Diagnostic (CDx) market by keeping the information simple, relevant, accurate, and to the point. The research report highlights the inner and outer examination of the Companion Diagnostic (CDx) market. This intelligence report includes investigations based on Current scenarios,
Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market …
The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) report compiles the market information depending upon market development and growth factors, optimizing the growth path. In addition, it highlights the strategies and market share of the leading vendors in the particular market. The report follows a robust research methodology model that helps to make informed decisions. It obtains both qualitative and quantitative market information supported by primary research. The Pharmacogenomics Technology
Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market …
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market survey report has been prepared by conducting market research in a
Pharmacogenomics Technology (Theranostics & Cdx) Market 2021 Analysis by Size, S …
This comprehensive Report on the Pharmacogenomics Technology (Theranostics & Cdx) Market provides real information about the statistics and state of the global and regional market. Its scope study extends from the market situation to comparative pricing between the main players, spending in specific market areas, and profits. It represents a comprehensive and succinct analysis report of the main competitor and price statistics with a view to helping beginners establish their
Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Mark …
This report studies the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market by companies, region, type and end-use industry. Get Sample Copy of This Report @ https://www.researchtrades.com/request-sample/1644663 In 2017, the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market size was million US$ and it is expected to reach million US$ by the end of 2025,
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Sale …
This report studies the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market, analyzes and researches the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Qiagen NV GE Healthcare Agilent Technologies F Hoffman La Roche Foundation Medicine Thermo Fisher Scientific Inc. Leica Biosystems Nussloch GmBH Pfizer Get the sample copy of report : https://www.marketresearchreports.biz/sample/sample/1486733 Market segment by Regions/Countries, this report covers United States EU Japan China India Southeast